Abstract
Objective There is a need to better understand recent trends in stimulant usage. This report compares the pharmacoepidemiology of three Schedule II stimulants in the United States from 2010 – 2017.
Methods Drug weights were extracted from the Automated Reports and Consolidated Ordering Systems (ARCOS) for amphetamine, methylphenidate, and lisdexamfetamine. Total grams per drug were averaged across all states and compared from 2010–2017. Median stimulant daily dosage per patient user was determined from electronic medical records for a regional analysis.
Results There was a rise in amphetamine (+67.5%) and lisdexamfetamine (+76.7%) use from 2010–2017. The change in methylphenidate (−3.0%) was modest. Regional analysis indicated that persons/day usage of stimulants in the west was lower than that of other US regions from 2014–2017. There was a negative correlation (r(48) = −0.43 to −0.65, p < .05) between the percent Hispanic population per state and the daily dose/population per stimulant.
Conclusion The increasing amphetamine and lisdexamfetamine, but not methylphenidate, use may be explained by a rise in adult ADHD diagnoses and treatment. Regional analysis indicates that the use of stimulants in the west may be distinct from that in other regions. The lower stimulant use in areas with greater Hispanic population may reflect socioeconomic factors. Further research is needed on social factors impacting stimulant use and reasons for the pronounced regional variance.
Competing Interest Statement
BJP is part of an osteoarthritis research team supported by Pfizer. The other authors have no conflicts of interest to declare.
Funding Statement
NJC, BDG, CDTT, DNT, & BJP were supported by the Center of Excellence, Health Resources and Services Administration (D34HP31025). SMV was Summer Research Immersion Program recipient.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data is available from the Drug Enforcement Administration.
https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html